Women Infertility - Pipeline Review, H2 2017

  • ID: 4410071
  • Report
  • 187 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4P Therapeutics LLC
  • Bayer AG
  • Enteris BioPharma Inc
  • Isifer AB
  • Navya Biologicals Pvt Ltd
  • Ogeda SA
  • MORE
Women Infertility - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Pipeline Review, H2 2017, provides an overview of the Women Infertility (Women's Health) pipeline landscape.

Infertility refers to failure to conceive over the course of one full year. Women infertility is caused due to damage of fallopian tubes, ovulation disorders (polycystic ovary syndrome) and endometriosis. Symptoms include abnormal periods, weight gain, back pain, pelvic pain, and cramping. Risk factor of infertility includes smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes medications to stimulate ovulation and hormone therapies.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Women Infertility - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 7, 16, 14, 1, 22, 9 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 3 molecules, respectively.

Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4P Therapeutics LLC
  • Bayer AG
  • Enteris BioPharma Inc
  • Isifer AB
  • Navya Biologicals Pvt Ltd
  • Ogeda SA
  • MORE
Introduction

Women Infertility - Overview

Women Infertility - Therapeutics Development

Women Infertility - Therapeutics Assessment

Women Infertility - Companies Involved in Therapeutics Development

Women Infertility - Drug Profiles

Women Infertility - Dormant Projects

Women Infertility - Discontinued Products

Women Infertility - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Women Infertility, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Development by Companies, H2 2017 (Contd..2), H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2 2017 (Contd..2), H2

Products under Development by Companies, H2 2017 (Contd..3), H2

Products under Development by Companies, H2 2017 (Contd..4), H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Target, H2 2017 (Contd..1), H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Women Infertility - Pipeline by 4P Therapeutics LLC, H2

Women Infertility - Pipeline by AbbVie Inc, H2

Women Infertility - Pipeline by Addex Therapeutics Ltd, H2

Women Infertility - Pipeline by APAvadis Biotechnologies Srl, H2

Women Infertility - Pipeline by ASKA Pharmaceutical Co Ltd, H2

Women Infertility - Pipeline by Astellas Pharma Inc, H2

Women Infertility - Pipeline by Bayer AG, H2

Women Infertility - Pipeline by Cadila Healthcare Ltd, H2

Women Infertility - Pipeline by Dong-A Socio Holdings Co Ltd, H2

Women Infertility - Pipeline by ElexoPharm GmbH, H2

Women Infertility - Pipeline by EndoCeutics Inc, H2

Women Infertility - Pipeline by Enteris BioPharma Inc, H2

Women Infertility - Pipeline by Evotec AG, H2

Women Infertility - Pipeline by Ferring International Center SA, H2

Women Infertility - Pipeline by Forendo Pharma Ltd, H2

Women Infertility - Pipeline by Glycotope GmbH, H2

Women Infertility - Pipeline by Isifer AB, H2

Women Infertility - Pipeline by Kissei Pharmaceutical Co Ltd, H2

Women Infertility - Pipeline by Lipicard Technologies Ltd, H2

Women Infertility - Pipeline by Livzon Pharmaceutical Group Inc, H2

Women Infertility - Pipeline by Luye Pharma Group Ltd, H2

Women Infertility - Pipeline by Myovant Sciences Ltd, H2

Women Infertility - Pipeline by Navya Biologicals Pvt Ltd, H2

Women Infertility - Pipeline by Nippon Shinyaku Co Ltd, H2

Women Infertility - Pipeline by Nora Therapeutics Inc, H2

Women Infertility - Pipeline by ObsEva SA, H2

Women Infertility - Pipeline by Ogeda SA, H2

Women Infertility - Pipeline by Pangen Biotech Inc., H2

Women Infertility - Pipeline by Pantec Biosolutions AG, H2

Women Infertility - Pipeline by Philogen SpA, H2

Women Infertility - Pipeline by Repros Therapeutics Inc, H2

Women Infertility - Pipeline by Richter Gedeon Nyrt, H2

Women Infertility - Pipeline by SK Chemicals Co Ltd, H2

Women Infertility - Pipeline by Takeda Pharmaceutical Co Ltd, H2

Women Infertility - Pipeline by ValiRx Plc, H2

Women Infertility - Pipeline by Viramal Ltd, H2

Women Infertility - Dormant Projects, H2

Women Infertility - Dormant Projects, H2 2017 (Contd..1), H2

Women Infertility - Dormant Projects, H2 2017 (Contd..2), H2

Women Infertility - Discontinued Products, H2

List of Figures

Number of Products under Development for Women Infertility, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4P Therapeutics LLC
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • APAvadis Biotechnologies Srl
  • ASKA Pharmaceutical Co Ltd
  • Astellas Pharma Inc
  • Bayer AG
  • Cadila Healthcare Ltd
  • Dong-A Socio Holdings Co Ltd
  • ElexoPharm GmbH
  • EndoCeutics Inc
  • Enteris BioPharma Inc
  • Evotec AG
  • Ferring International Center SA
  • Forendo Pharma Ltd
  • Glycotope GmbH
  • Isifer AB
  • Kissei Pharmaceutical Co Ltd
  • Lipicard Technologies Ltd
  • Livzon Pharmaceutical Group Inc
  • Luye Pharma Group Ltd
  • Myovant Sciences Ltd
  • Navya Biologicals Pvt Ltd
  • Nippon Shinyaku Co Ltd
  • Nora Therapeutics Inc
  • ObsEva SA
  • Ogeda SA
  • Pangen Biotech Inc.
  • Pantec Biosolutions AG
  • Philogen SpA
  • Repros Therapeutics Inc
  • Richter Gedeon Nyrt
  • SK Chemicals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • ValiRx Plc
  • Viramal Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll